Matches in Wikidata for { <http://www.wikidata.org/entity/Q37331159> ?p ?o ?g. }
- Q37331159 description "article científic" @default.
- Q37331159 description "article scientifique" @default.
- Q37331159 description "articolo scientifico" @default.
- Q37331159 description "artigo científico" @default.
- Q37331159 description "artículu científicu espublizáu en 2013" @default.
- Q37331159 description "bilimsel makale" @default.
- Q37331159 description "scientific article published on 23 September 2013" @default.
- Q37331159 description "vedecký článok" @default.
- Q37331159 description "vetenskaplig artikel" @default.
- Q37331159 description "videnskabelig artikel" @default.
- Q37331159 description "vědecký článek" @default.
- Q37331159 description "wetenschappelijk artikel" @default.
- Q37331159 description "wissenschaftlicher Artikel" @default.
- Q37331159 description "наукова стаття, опублікована у вересні 2013" @default.
- Q37331159 description "научни чланак" @default.
- Q37331159 description "مقالة علمية نشرت في 23 سبتمبر 2013" @default.
- Q37331159 name "Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a ≥52-week randomized, double-blind study" @default.
- Q37331159 name "Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a ≥52-week randomized, double-blind study" @default.
- Q37331159 name "Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a ≥52-week randomized, double-blind study" @default.
- Q37331159 type Item @default.
- Q37331159 label "Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a ≥52-week randomized, double-blind study" @default.
- Q37331159 label "Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a ≥52-week randomized, double-blind study" @default.
- Q37331159 label "Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a ≥52-week randomized, double-blind study" @default.
- Q37331159 prefLabel "Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a ≥52-week randomized, double-blind study" @default.
- Q37331159 prefLabel "Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a ≥52-week randomized, double-blind study" @default.
- Q37331159 prefLabel "Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a ≥52-week randomized, double-blind study" @default.
- Q37331159 P1433 Q37331159-83E01C37-9A26-4540-8EDD-2FB456DE1EF4 @default.
- Q37331159 P1476 Q37331159-6D8ACBBB-C7E4-49EB-A62B-96ADB71C7589 @default.
- Q37331159 P2093 Q37331159-3F46B212-E1DF-411A-A81F-29895066D545 @default.
- Q37331159 P2093 Q37331159-48D56D9A-EB16-4B52-878D-8E9E39FD2313 @default.
- Q37331159 P2093 Q37331159-5093DC6A-D91E-45C5-8BE9-34C81C6FAA93 @default.
- Q37331159 P2093 Q37331159-720C3B50-89AD-4789-8232-46C9E928BC7A @default.
- Q37331159 P2093 Q37331159-8D625B2C-FBF5-4C16-97B0-CE37B620B6BB @default.
- Q37331159 P2093 Q37331159-FA240025-A082-4739-A0F7-B1238BBEFCA7 @default.
- Q37331159 P275 Q37331159-f9f59633-5c9d-4312-9666-779ca771e954 @default.
- Q37331159 P2860 Q37331159-038418E5-AAFF-4756-9D0A-3B005F0BE3B1 @default.
- Q37331159 P2860 Q37331159-173D230E-72C2-477E-B1A5-15CCCE660B7F @default.
- Q37331159 P2860 Q37331159-291E5F8F-B522-4561-896E-6BE0C5F0A731 @default.
- Q37331159 P2860 Q37331159-4092C7AE-003C-4B6D-96E9-07A77310D318 @default.
- Q37331159 P2860 Q37331159-40FC81C7-8D93-4645-9D35-8BA845CAA144 @default.
- Q37331159 P2860 Q37331159-4BA2FFD9-92D7-4D4D-B319-C43096F77F51 @default.
- Q37331159 P2860 Q37331159-505D3A43-B3F0-415F-A099-486ABF3B8D6C @default.
- Q37331159 P2860 Q37331159-514800FA-B621-406F-8B79-FF5C37B2FBD4 @default.
- Q37331159 P2860 Q37331159-6DAC3AD8-788D-452A-9C18-89BFA87E1345 @default.
- Q37331159 P2860 Q37331159-85423C7F-5902-453E-8F65-9F89591E3C5D @default.
- Q37331159 P2860 Q37331159-890FF613-29B4-4D76-8307-09C2C2E36D0D @default.
- Q37331159 P2860 Q37331159-98EE6817-686D-480B-BF6E-67FA2F22B2D7 @default.
- Q37331159 P2860 Q37331159-B2D38D3C-451B-4062-A9D8-F71FA9F04705 @default.
- Q37331159 P2860 Q37331159-B40EBF9A-EC3B-4234-AB38-1AD8417165CC @default.
- Q37331159 P2860 Q37331159-C56B858D-D948-4156-9410-3718E14F8D67 @default.
- Q37331159 P2860 Q37331159-C7D2FD03-D791-4A77-B12A-AB61C54AB8C9 @default.
- Q37331159 P2860 Q37331159-D9B77D20-7CB5-4952-9028-86FEAFC332AA @default.
- Q37331159 P2860 Q37331159-E0583E02-7967-43B4-B7A3-395AEEB2268A @default.
- Q37331159 P2860 Q37331159-EACFF32B-90AF-4703-A294-04E1530FB418 @default.
- Q37331159 P2860 Q37331159-EEAD157A-1103-45F2-968E-8E09EBCF3286 @default.
- Q37331159 P304 Q37331159-F18130B7-A6F4-4612-AD1D-0A2E65361241 @default.
- Q37331159 P31 Q37331159-34076A3D-E10E-4008-BA06-B938D28AAE7C @default.
- Q37331159 P356 Q37331159-8191246F-29B7-4DE4-88F0-2E9CF4173340 @default.
- Q37331159 P407 Q37331159-051B5E14-D667-40D7-A852-A6F8AD5A9538 @default.
- Q37331159 P433 Q37331159-A5A46809-3D16-45CD-ADCE-B7121120BAB4 @default.
- Q37331159 P478 Q37331159-6C3F3845-8BA8-4116-8C0F-91D10797667A @default.
- Q37331159 P50 Q37331159-7A8DFE66-75E4-4822-93DC-80240D81B110 @default.
- Q37331159 P50 Q37331159-CA261A9E-81E3-4CF5-9AA1-ED475C5D53E5 @default.
- Q37331159 P577 Q37331159-9C521E77-093D-48CB-919B-30530B26BE76 @default.
- Q37331159 P5875 Q37331159-86044C50-AC54-4E54-9187-88187BCA11A8 @default.
- Q37331159 P6216 Q37331159-43496a82-8a30-48f6-95fe-fe29ded08618 @default.
- Q37331159 P698 Q37331159-EC9044F3-C451-4D14-8E6E-8560AE43E8B2 @default.
- Q37331159 P921 Q37331159-1455826B-98A7-4655-A484-AB37DCAFC6C4 @default.
- Q37331159 P921 Q37331159-2EBCABC8-BDC5-4CFB-B2E8-F1571CC461F6 @default.
- Q37331159 P921 Q37331159-8ECA160A-BF79-48FA-B6EA-237918BC7A91 @default.
- Q37331159 P932 Q37331159-7065B521-1F1F-4EB2-8561-DE1FEED036E8 @default.
- Q37331159 P356 DC12-2718 @default.
- Q37331159 P698 24062327 @default.
- Q37331159 P1433 Q5270111 @default.
- Q37331159 P1476 "Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a ≥52-week randomized, double-blind study" @default.
- Q37331159 P2093 "Hans-Juergen Woerle" @default.
- Q37331159 P2093 "Sabine Pinnetti" @default.
- Q37331159 P2093 "Sandra Thiemann" @default.
- Q37331159 P2093 "Sanjay Patel" @default.
- Q37331159 P2093 "Santiago Durán-Garcia" @default.
- Q37331159 P2093 "Sudipta Bhattacharya" @default.
- Q37331159 P275 Q19125045 @default.
- Q37331159 P2860 Q22241288 @default.
- Q37331159 P2860 Q28273497 @default.
- Q37331159 P2860 Q36087961 @default.
- Q37331159 P2860 Q36560252 @default.
- Q37331159 P2860 Q38467033 @default.
- Q37331159 P2860 Q40164421 @default.
- Q37331159 P2860 Q43187035 @default.
- Q37331159 P2860 Q43189640 @default.
- Q37331159 P2860 Q43275817 @default.
- Q37331159 P2860 Q43587844 @default.
- Q37331159 P2860 Q44631767 @default.
- Q37331159 P2860 Q45250947 @default.
- Q37331159 P2860 Q45350582 @default.
- Q37331159 P2860 Q46653146 @default.
- Q37331159 P2860 Q46966714 @default.
- Q37331159 P2860 Q51178386 @default.
- Q37331159 P2860 Q51361433 @default.
- Q37331159 P2860 Q51474878 @default.